- Home
- SYRS vs CLGN Comparison
SYRS vs CLGN Comparison
Compare SYRS & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRS
- CLGN
- Stock Information
- Founded
- SYRS 2011
- CLGN 2004
- Country
- SYRS United States
- CLGN Israel
- Employees
- SYRS N/A
- CLGN N/A
- Industry
- SYRS Biotechnology: Pharmaceutical Preparations
- CLGN Industrial Specialties
- Sector
- SYRS Health Care
- CLGN Health Care
- Exchange
- SYRS Nasdaq
- CLGN Nasdaq
- Market Cap
- SYRS 52.5M
- CLGN 44.1M
- IPO Year
- SYRS 2016
- CLGN N/A
- Fundamental
- Price
- SYRS $0.26
- CLGN $4.17
- Analyst Decision
- SYRS Hold
- CLGN Strong Buy
- Analyst Count
- SYRS 5
- CLGN 2
- Target Price
- SYRS $3.00
- CLGN $12.50
- AVG Volume (30 Days)
- SYRS 23.8M
- CLGN 17.9K
- Earning Date
- SYRS 10-31-2024
- CLGN 11-27-2024
- Dividend Yield
- SYRS N/A
- CLGN N/A
- EPS Growth
- SYRS N/A
- CLGN N/A
- EPS
- SYRS N/A
- CLGN N/A
- Revenue
- SYRS $386,000.00
- CLGN $689,000.00
- Revenue This Year
- SYRS N/A
- CLGN N/A
- Revenue Next Year
- SYRS $1,011.11
- CLGN $670.03
- P/E Ratio
- SYRS N/A
- CLGN N/A
- Revenue Growth
- SYRS N/A
- CLGN N/A
- 52 Week Low
- SYRS $0.18
- CLGN $3.61
- 52 Week High
- SYRS $8.17
- CLGN $6.99
- Technical
- Relative Strength Index (RSI)
- SYRS 28.67
- CLGN 50.20
- Support Level
- SYRS $0.18
- CLGN $3.97
- Resistance Level
- SYRS $0.37
- CLGN $4.41
- Average True Range (ATR)
- SYRS 0.22
- CLGN 0.26
- MACD
- SYRS -0.23
- CLGN 0.06
- Stochastic Oscillator
- SYRS 2.39
- CLGN 57.22
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.